These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23463207)

  • 61. Advances in newly developing therapy for chronic hepatitis C virus infection.
    Pockros PJ
    Front Med; 2014 Jun; 8(2):166-74. PubMed ID: 24871445
    [TBL] [Abstract][Full Text] [Related]  

  • 62. New developments in the discovery of agents to treat hepatitis C.
    Rönn R; Sandström A
    Curr Top Med Chem; 2008; 8(7):533-62. PubMed ID: 18473882
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Direct-acting antiviral agents and the path to interferon independence.
    Schmidt WN; Nelson DR; Pawlotsky JM; Sherman KE; Thomas DL; Chung RT
    Clin Gastroenterol Hepatol; 2014 May; 12(5):728-37. PubMed ID: 23872239
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Structure-based design of hepatitis C virus inhibitors.
    Smith RM; Wu GY
    J Viral Hepat; 2003 Nov; 10(6):405-12. PubMed ID: 14633172
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Chutes and ladders in hepatitis C nucleoside drug development.
    Coats SJ; Garnier-Amblard EC; Amblard F; Ehteshami M; Amiralaei S; Zhang H; Zhou L; Boucle SR; Lu X; Bondada L; Shelton JR; Li H; Liu P; Li C; Cho JH; Chavre SN; Zhou S; Mathew J; Schinazi RF
    Antiviral Res; 2014 Feb; 102():119-47. PubMed ID: 24275341
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Emerging Trends in Non-Interferon-Based Genotype-Specific Antiviral Agents: Pharmaceutical Perspectives.
    Farooq T; Hameed A; Rehman K; Ibrahim M; Ahmed M; Gulzar T; Akash MSH
    Crit Rev Eukaryot Gene Expr; 2017; 27(4):305-319. PubMed ID: 29283325
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Nanomedicine as a future therapeutic approach for Hepatitis C virus.
    Abd Ellah NH; Tawfeek HM; John J; Hetta HF
    Nanomedicine (Lond); 2019 Jun; 14(11):1471-1491. PubMed ID: 31166139
    [TBL] [Abstract][Full Text] [Related]  

  • 68. What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals?
    Hunt D; Pockros P
    Curr Gastroenterol Rep; 2013 Jan; 15(1):303. PubMed ID: 23250703
    [TBL] [Abstract][Full Text] [Related]  

  • 69. HCV drug discovery aimed at viral eradication.
    Schinazi RF; Bassit L; Gavegnano C
    J Viral Hepat; 2010 Feb; 17(2):77-90. PubMed ID: 20040045
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets.
    Alazard-Dany N; Denolly S; Boson B; Cosset FL
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30621318
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hepatitis C virus experimental model systems and antiviral drug research.
    Uprichard SL
    Virol Sin; 2010 Aug; 25(4):227-45. PubMed ID: 20960298
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Anti-hepatitis C virus strategy targeting host entry factor claudin-1].
    Fukasawa M
    Uirusu; 2015; 65(2):245-254. PubMed ID: 27760923
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015.
    Brouard C; Boussac-Zarebska M; Silvain C; Durand J; de Lédinghen V; Pillonel J; Delarocque-Astagneau E
    BMC Infect Dis; 2017 Dec; 17(1):784. PubMed ID: 29262788
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.
    Ahmad T; Yin P; Saffitz J; Pockros PJ; Lalezari J; Shiffman M; Freilich B; Zamparo J; Brown K; Dimitrova D; Kumar M; Manion D; Heath-Chiozzi M; Wolf R; Hughes E; Muir AJ; Hernandez AF
    Hepatology; 2015 Aug; 62(2):409-16. PubMed ID: 25251156
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Treatment of chronic hepatitis C--new drugs, new hope].
    Pawłowska M; Halota W
    Przegl Epidemiol; 2006; 60(4):725-30. PubMed ID: 17682754
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The fragile relationship between hepatitis C virus and its human host.
    Schooley RT
    Top Antivir Med; 2014 Jan; 21(5):148-51. PubMed ID: 24531554
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Molecular diagnostic and predictive tests in the evolution of chronic hepatitis C anti-viral therapies.
    Colucci G
    BMC Infect Dis; 2012; 12 Suppl 2(Suppl 2):S8. PubMed ID: 23173776
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Chronic hepatitis C: standard of care and perspective].
    Aghemo A; De Nicola S
    Recenti Prog Med; 2016 Jul; 107(7):349-54. PubMed ID: 27571464
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hepatitis C Virus: 30 Years after Its Discovery.
    Houghton M
    Cold Spring Harb Perspect Med; 2019 Dec; 9(12):. PubMed ID: 31501269
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Current treatment of chronic hepatitis C in China: Dilemma and potential problems.
    Han QY; Liu ZW
    World J Gastroenterol; 2016 May; 22(19):4615-8. PubMed ID: 27217693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.